Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/103021
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHopkins, A.-
dc.contributor.authorMoghaddami, M.-
dc.contributor.authorFoster, D.-
dc.contributor.authorProudman, S.-
dc.contributor.authorUpton, R.-
dc.contributor.authorWiese, M.-
dc.date.issued2017-
dc.identifier.citationDrug Metabolism and Disposition, 2017; 45(1):8-16-
dc.identifier.issn0090-9556-
dc.identifier.issn1521-009X-
dc.identifier.urihttp://hdl.handle.net/2440/103021-
dc.description.abstractLeflunomide's active metabolite teriflunomide inhibits dihydro-oroate dehydrogenase (DHODH), an enzyme essential to proliferation of T-lymphocytes. As teriflunomide must reach the target site to have this effect, this study assessed the distribution of teriflunomide into T-lymphocytes, as intracellular concentrations may be a superior response biomarker to plasma concentrations. CD3 MicroBeads (MiltenyiBiotec) were used to extract CD3(+) T-cells from the peripheral blood of patients with rheumatoid arthritis whom were taking a stable dose of leflunomide. Unbound plasma and intra-CD3(+) T-cell teriflunomide concentrations were quantified using liquid chromatography-mass spectrometry (LC-MSMS). Concentration (log transformed) and partition differences were assessed through paired Student's t-tests. Sixteen patients provided plasma steady-state teriflunomide samples, and eight provided a sample 6-12 weeks later. At time-point one, the geometric mean teriflunomide concentration (range) in CD3(+) T-cells was 18.12 ug/L (6.15 - 42.26 ug/L) compared to 69.75 ug/L (32.89 - 263.1 ug/L) unbound in plasma (p<0.001). The mean partition coefficient (range) for unbound plasma teriflunomide into CD3(+) T-cells was 0.295 (0.092 - 0.632), which was significantly different from unity (p<0.001). The median (range) change in teriflunomide concentration between the two time points was 14% (-10% to 40%) in unbound plasma and -29% (-69 to 138%) for CD3(+) T-cells. Since teriflunomide concentrations in CD3(+) T-cells were lower and displayed a higher intra-individual variability than the unbound plasma concentrations, its applicability as a therapeutic drug monitoring marker may be limited.-
dc.description.statementofresponsibilityAshley M Hopkins, Mahin Moghaddami, David JR Foster, Susanna M Proudman, Richard N Upton, Michael D Wiese-
dc.language.isoen-
dc.publisherAmerican Society for Pharmacology and Experimental Therapeutics-
dc.rights© American Society for Pharmacology and Experimental Therapeutics-
dc.subjectmass spectrometry/MS-
dc.subjectpharmacokinetics-
dc.titleIntracellular CD3⁺ T-lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration-
dc.typeJournal article-
dc.identifier.doi10.1124/dmd.116.071985-
pubs.publication-statusPublished-
dc.identifier.orcidFoster, D. [0000-0002-7345-4084]-
dc.identifier.orcidProudman, S. [0000-0002-3046-9884]-
dc.identifier.orcidUpton, R. [0000-0001-9996-4886]-
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.